▲ +4.43% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Turning Point Therapeutics in the last 3 months. The average price target is $137.43, with a high forecast of $160.00 and a low forecast of $122.00. The average price target represents a 4.43% upside from the last price of $131.60.
The current consensus among 7 investment analysts is to buy stock in Turning Point Therapeutics.
Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naÃ¯ve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. The company was founded in 2013 and is headquartered in San Diego, California.